The expression of p53 can be decreased in a number of ways, including MDM2 overexpression, deletion of its chromosome, 17p, and inactivating p53 mutations (seen in ~8% of newly-diagnosed patients) to promote proliferation of myeloma cells (130–132). Here, TP53 is linked to plasma cell myeloma.